Prof. Bisdas wins Neuro-Radiologist of the Year award!

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Many congratulations to Prof. Sotirios Bisdas, IAG’s Therapeutic Area Head, who received the Neuroradiologist of the Year Award in 2022, supported by the 11th International Day of Radiology #IDoR2022.

Our warmest congratulations to Prof. Bisdas, the true industry innovator and one of the most inspiring and dedicated professionals of our times!

‘Being successful in radiology takes hard work. One can’t afford to stay on autopilot in today’s rapidly changing research environments and still expect to remain on top. I believe in a culture of inclusion, purpose, support, and empathy for our consultants, academics, and clinical scientists putting patients in the centre of our work,’ said Prof. Bisdas.

Prof. Sotirios Bisdas, the Head of IAG’s Neuro-Oncology and Neuro-Degeneration is also a consultant neuroradiologist and MRI lead in the Department of Neuroradiology at the National Hospital for Neurology in London, UK, senior lecturer in neuroradiology at the Institute of Neurology University College London, and professor of radiology at Eberhard Karls University in Tübingen, Germany.

He finished his MD thesis in psychiatry after joint studies at University of Athens, Greece and University of Mainz, Germany. Dr  Bisdas was trained in Radiology and Neuroradiology at Hannover Medical School, University of Frankfurt, and University of Tübingen. He has completed a post-doctoral scholarship in Neuroradiology Research at the Medical University of South Carolina, USA. He holds a MSc degree in “Advanced Oncology” from University of Ulm, Germany and is also fellow of the European Society of Head and Neck Radiology. His expertise fields include advanced CT, intraoperative MRI, advanced and functional MRI and molecular MR-PET imaging in brain diseases.

He has authored more than 130 peer-reviewed publications (h-index > 30) and seven book chapters.

Currently, he is clinical lead of the flagship program in neuro-oncology, a joint initiative of the Institute of Healthcare Engineering and the National Hospital of Neurology and Neurosurgery. Dr Bisdas serves as member of the editorial board of several leading journals in radiology and neuroradiology, is reviewer for leading journals in neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

News
Events

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

A collaboration between IAG, Image Analysis Group, the University of Leeds, and Prof. Francesco Del Galdo brings a new AI-driven endpoint into clinical trials.

For immediate release: 21 October 2022

Digital Artery Volume Index (DAVIX©) is a novel quantitative MRI-based scoring for the assessment of the blood flow in the arteries.

DAVIX© has been validated as a predictor of the onset of Digital Ulcers in Systemic Sclerosis patients. This innovative methodology is based on the Time-of-Flight Magnetic Resonance Imaging (MRI) angiography and allows to quantitatively assess digital arterial blood flow.

Thus, predicting the onset of Digital Ulcers (DUs) in Systemic Sclerosis (SSc) patients.

The methodology was developed as part of IAG’s DYNAMIKA cloud platform and is now accessible for use in clinical trials and clinical practice for research use. DAVIX© is being deployed by biotech and pharmaceutical companies in global clinical trials as a surrogate outcome measure of SSc vascular disease activity.

This robust methodology can be delivered to clinical sites, with over 100 imaging sites around the world already acquiring the specific MRI data to allow for the assessment of SSc patients with DAVIX©.

DAVIX© is the first MRI quantitative measure of vascular disease in Systemic Sclerosis. Building on its predictive value for active vascular disease, it is now tested in randomised clinical trials as stratification tool for vascular disease and as a surrogate endpoint for vasoactive interventions,” said Professor Francesco Del Galdo, University of Leeds.

The proprietary name of the endpoint DAVIX© has been copyrighted by the University of Leeds, with a lifetime licence assigned to IAG, Image Analysis Group.

“We look forward to seeing how this unique endpoint will help accelerating the speed of pharmaceutical R&D and most importantly improve therapeutic success for patients,“  said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

Neointima proliferation results in vascular wall thickening and gradual loss of luminal patency and is a key pathological feature of Systemic Sclerosis. It is a recognised culprit pathological lesion in Digital Ulcers, pulmonary hypertension and renal crisis.

We are delighted with the results of this collaboration. DAVIX© fits perfectly with IAG’s suite of advanced Artificial Intelligence (AI)-supported imaging methodologies and our strategy to make DYNAMIKA™ the leading image management platform for forward thinking drug developers, said Simon Hart, IAG’s Bio-Partnering Director.

IAG’s has brought technical capabilities and over 15 years of operational experience helping to optimize and standardize DAVIX© in clinical trials. This is a great compliment to all IAG’s teams involved into developing and deploying our Artificial Intelligence methodologies, across hundreds of globally distributed clinical sites, built on our DYNAMIKA™, IAG’s proprietary secure cloud based medical image management and review platform, “ added Prof. Jamshid Dehmeshki, CTO of IAG.  

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

News
Events

Meet IAG’s Team at DDW 2022, San Diego

Meet IAG’s Team at DDW 2022, San Diego

Meet IAG’s Team at DDW 2022, San Diego

Dr. Olga Kubassova, IAG’s CEO, and Simon Hart, IAG’s Bio-partnering Director, will be attending the Digestive Disease Week 2022 (DDW 2022) conference in San Diego, on May 21 – 24, 2022.

IAG’s team will be meeting with key biotech companies and addressing the challenges they face in pharmaceutical trials to explore IAG’s novel strategies, including advanced imaging biomarkers and Artificial Intelligence in precision medicine and drug development.

If you are not attending, schedule a call: imaging.experts@ia-grp.com

IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

Discover our risk assessment and management strategies to overcome the challenges in your trial by contacting IAG at imaging.experts@ia-grp.com

About DDW

Digestive Disease Week (DDW) is the most prestigious meeting in the world for GI professionals providing an unparalleled opportunity to delve into exciting new developments with leaders in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events